DEF 14A: The Cigna Group Aims for Continued Growth and Shareholder Value in 2024

The Cigna Group reports strong 2023 financial performance and outlines strategic priorities for continued growth and shareholder value in 2024.

Summary

• The Cigna Group delivered strong financial results in 2023, with total revenues growing to $195.3 billion, an 8% increase year-over-year.
• Shareholders net income for 2023 was $5.2 billion, or $17.39 per share, while adjusted income from operations reached $7.4 billion, or $25.09 per share.
• The company generated $11.8 billion in cash flow from operations and expanded its share repurchase authority to $11.3 billion.
• The Cigna Group expects to repurchase at least $5 billion in common stock by the end of the first half of 2024 and use the majority of its discretionary cash flow for share repurchases in 2024.
• The company is focused on expanding its reach and strengthening capabilities across its Evernorth Health Services and Cigna Healthcare platforms.
• A definitive agreement has been reached to sell the Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D, and CareAllies businesses to Health Care Service Corporation for approximately $3.7 billion, expected to be accretive to earnings per share in 2025.
• The Cigna Group is committed to advancing its Environmental, Social, and Governance (ESG) strategic framework, including addressing health disparities, supporting its global workforce, reducing its carbon footprint, and ensuring ethical business decisions.
• The company achieved its goal of $1 billion in annual total diverse supplier spend two years ahead of schedule.
• Dr. Philip Ozuah was appointed as a new independent director to the Board in June 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and strategic initiatives. The company is focused on growth, shareholder value, and ESG commitments.

Positives

• Strong financial performance in 2023 with revenue and adjusted income growth.
• Strategic focus on core businesses through the sale of Medicare Advantage and related businesses.
• Commitment to returning capital to shareholders through share repurchases.
• Advancement of ESG initiatives and recognition as a corporate sustainability leader.
• Expansion of services and solutions in key areas like pharmacy benefits management and virtual care.
• Continued growth in medical customer base.
• Strong Medicare Stars Quality Rating.

Negatives

• Shareholders net income decreased from $6.7 billion in 2022 to $5.2 billion in 2023.
• The sale of Medicare Advantage and related businesses may impact future revenue streams.

Risks

• The rapidly changing health care landscape and pharmacological innovation require continuous adaptation.
• Maintaining competitive benefit offerings and disciplined pricing in the Medicare Advantage and Individual Exchange businesses.
• Successfully integrating and leveraging new partnerships and acquisitions.
• Managing the complexity and costs of obesity, diabetes, and cardiovascular disease.
• Ensuring data protection and compliance with evolving regulations.

Future Outlook

The Cigna Group will continue to expand its reach and strengthen capabilities across its Evernorth Health Services and Cigna Healthcare platforms, focusing on innovation and growth in government services.

Management Comments

• In 2023, The Cigna Group executed well and delivered sustained growth and strong performance.
• We enter 2024 with momentum and remain focused on advancing our strategy and investing in our future.
• We will continue to expand our reach and strengthen capabilities across our Evernorth Health Services and Cigna Healthcare platforms.
• We will evolve and grow our businesses to deliver value for our shareholders while also building on our work toward a health care system that benefits every individual and every community.

Industry Context

The announcement highlights the company's efforts to adapt to the rapidly changing health care landscape, including pharmacological innovation and the growing need for mental health care. The company is also focused on expanding its reach into new markets, such as the Kingdom of Saudi Arabia.

Comparison to Industry Standards

• The document mentions comparisons to S&P benchmarks on mean age, tenure, and gender and ethnic diversity of the board.
• The company's TSR is compared to a peer group for performance-based compensation.
• The company benchmarks compensation against a compensation peer group and a general industry peer group.

Management Changes

Related Party Transactions

• A member of Mr. Wiseman's family is an employee of The Cigna Group, with compensation determined according to standard company practices.

Stakeholder Impact

• Shareholders will benefit from the company's focus on growth, profitability, and return of capital.
• Employees will be supported through health and well-being programs, diversity and inclusion initiatives, and career development opportunities.
• Customers and clients will benefit from improved access to care, affordable medicines, and innovative solutions.
• Communities will benefit from the company's commitment to addressing health disparities and supporting local initiatives.

Next Steps

• Shareholders are invited to attend the 2024 Annual Meeting of Shareholders on April 24, 2024.
• The company will continue to innovate and grow its government services business in its high-performing Evernorth portfolio.
• The company plans to review its ESG focus areas and conduct a formal ESG double materiality assessment in 2024.

Key Dates

Keywords

Cigna, financial performance, shareholder value, healthcare, ESG, Medicare Advantage, Evernorth, pharmacy benefits, executive compensation, corporate governance